BARD1 and cancer: Loss of E3 ligase activity leads to HR deficiency (HRD), a phenotype similar to that caused by the cancer-associated BRCA1 C61G mutation, which weakens the BRCA1-BARD1 interaction and disrupts BRCA1’s binding to E2 enzymes, thereby abolishing the ligase function [37,38,39].